Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2023-03-29 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
天健会计师事务所（特殊普通合伙）关于江苏德源药业股份有限公司募集资金年度存放与使用情况鉴证报告
Regulatory Filings
2023-03-29 Chinese
开源证券股份有限公司关于江苏德源药业股份有限公司使用部分闲置募集资金进行现金管理的核查意见
Regulatory Filings
2023-03-29 Chinese
关于2021年限制性股票定向回购股份方案的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the repurchase and cancellation of restricted shares under the 2021 restricted stock incentive plan. It details the board and supervisory meetings approving the repurchase, the basis and type of repurchase, the number of shares involved, pricing adjustments, and the impact on share capital and equity structure. It also includes management's analysis of the repurchase's impact on financial status and creditor protection measures. The document is focused on a share repurchase related to stock incentives, not a full financial report or earnings release. It is not a regulatory filing or announcement of a report publication but a substantive announcement about a transaction in own shares (share buyback and cancellation). Therefore, the appropriate classification is Transaction in Own Shares (POS). The document length and detail support this classification with high confidence.
2023-03-29 Chinese
关于2022年年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2022 Annual Special Report on the Deposit and Actual Use of Raised Funds" by Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the amount of funds raised through stock issuance, the timing of fund receipt, the specific use of these funds, the balance remaining, and compliance with relevant laws and regulations. It includes detailed financial figures related to fundraising, usage, and management of the raised capital, as well as auditor and sponsor institution opinions. The document is a comprehensive report on the use of capital raised by the company, focusing on fundraising activities and the deployment of those funds, rather than a general annual report or earnings release. This matches the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes. The document is substantive and over 10,000 characters, so it is not merely an announcement of a report but the report itself.
2023-03-29 Chinese
2022年年度报告摘要
Annual Report Classification · 95% confidence The document is titled '年度报告摘要 2022' which translates to 'Annual Report Summary 2022'. It contains detailed financial data for the year 2022, including assets, net profit, earnings per share, and shareholder structure. It also includes management assurances about the accuracy of the report, audit opinions, and dividend distribution plans. The length of the document (7370 characters) and the presence of substantive financial data and analysis indicate this is the actual annual report or a summary thereof, not just an announcement or a certification. The content aligns with the definition of an Annual Report (10-K) as it covers company activity and full financial performance for the fiscal year 2022. Therefore, the document should be classified as an Annual Report (10-K). FY 2022
2023-03-29 Chinese
以自有闲置资金进行委托理财的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the use of idle funds for entrusted financial management. It details the purpose, amount, methods, risk analysis, and approval procedures related to the company's investment of idle funds in low-risk financial products. The document includes no financial statements or comprehensive financial data but rather describes a financing activity and related corporate governance steps. It is not a full financial report, earnings release, or audit report. The content fits best under Capital/Financing Update (CAP) as it concerns the company's capital usage and financing activities.
2023-03-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.